The Lonza Small Molecules facility in Tampa, FL, USA has upgraded its powder analysis capabilities, the company said. In May 2022, Lonza announced that it was expanding its dry powder testing facilities in Tampa in order to increase its DPI development capacity.
According to Lonza, the Tampa site recently added a Freeman Technologies FT4 universal powder flow tester and a Malvern Panalytical Morphologi 4 morphologically-directed Raman spectroscopy particle characterization system, both of which will support development of inhaled dry powder formulations.
Lonza Tampa Pre-Formulation Team Lead Mark Cappucci commented, “With the enhanced characterization capabilities and tools at our Tampa facility, we can now better understand powder behaviors and – in turn – optimize drug product formulations for our customers. This is an important development in the context of the increasing complexity of molecules in the pipeline.”
Read the Lonza press release.
